HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Role of metallothioneins as danger signals in the pathogenesis of colitis.

Abstract
Inflammatory bowel diseases (IBDs) are recurrent intestinal pathologies characterized by a compromised epithelial barrier and an exaggerated immune activation. Mediators of immune cell infiltration may represent new therapeutic opportunities. Metallothioneins (MTs) are stress-responsive proteins with immune-modulating functions. Metallothioneins have been linked to IBDs, but their role in intestinal inflammation is inconclusive. We investigated MT expression in colonic biopsies from IBDs and acute infectious colitis patients and healthy controls and evaluated MT's role in experimental colitis using MT knockout mice and anti-MT antibodies. Antibody potential to target extracellular MT and its mechanism was tested in vitro. Biopsies of patients with active colitis showed infiltration of MT-positive cells in a pattern that correlated with the grade of inflammation. MT knockout mice displayed less severe acute dextran sulphate sodium (DSS)-induced colitis compared to congenic wild-type mice based on survival, weight loss, colon length, histological inflammation and leukocyte infiltration. Chronic DSS-colitis confirmed that Mt1 and Mt2 gene disruption enhances clinical outcome. Blockade of extracellular MT with antibodies reduced F4/80-positive macrophage infiltration in DSS- and trinitrobenzene sulphonic acid-colitis, with a tendency towards a better outcome. Whole-body single-photon emission computer tomography of mice injected with radioactive anti-MT antibodies showed antibody accumulation in the colon during colitis and clearance during recovery. Necrotic and not apoptotic cell death resulted in western blot MT detection in HT29 cell supernatant. In a Boyden chamber migration assay, leukocyte attraction towards the necrotic cell supernatant could be abolished with anti-MT antibody, indicating the chemotactic potential of endogenous released MT. Our results show that human colitis is associated with infiltration of MT-positive inflammatory cells. Since antibody blockade of extracellular MT can reduce colitis in mice, MT may act as a danger signal and may represent a novel target for reducing leukocyte infiltration and inflammation in IBD patients.
AuthorsLindsey Devisscher, Pieter Hindryckx, Michael A Lynes, Anouk Waeytens, Claude Cuvelier, Filip De Vos, Christian Vanhove, Martine De Vos, Debby Laukens
JournalThe Journal of pathology (J Pathol) Vol. 233 Issue 1 Pg. 89-100 (May 2014) ISSN: 1096-9896 [Electronic] England
PMID24452846 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2014 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Chemical References
  • Antibodies
  • Mt2 protein, mouse
  • metallothionein-1, mouse
  • Trinitrobenzenesulfonic Acid
  • Metallothionein
  • Dextran Sulfate
Topics
  • Acute Disease
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Animals
  • Antibodies (pharmacology)
  • Apoptosis
  • Biopsy
  • Case-Control Studies
  • Chemotaxis, Leukocyte
  • Chronic Disease
  • Colitis (chemically induced, genetics, immunology, metabolism, pathology, prevention & control)
  • Colon (drug effects, immunology, metabolism, pathology)
  • Dextran Sulfate
  • Disease Models, Animal
  • Female
  • HT29 Cells
  • Humans
  • Macrophages (immunology, metabolism)
  • Male
  • Metallothionein (antagonists & inhibitors, deficiency, genetics, immunology, metabolism)
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Middle Aged
  • Necrosis
  • Severity of Illness Index
  • Signal Transduction
  • Time Factors
  • Trinitrobenzenesulfonic Acid
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: